Zelboraf® (vemurafenib) – New warning

- The FDA approved an update to the *Warnings and Precautions* section of the Zelboraf (vemurafenib) drug label regarding Dupuytren's contracture and plantar fascial fibromatosis.

- Zelboraf is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

    — Zelboraf is not indicated for treatment of patients with wild-type BRAF melanoma.

- Dupuytren's contracture and plantar fascial fibromatosis have been reported with Zelboraf. The majority of cases were mild to moderate, but severe, disabling cases of Dupuytren's contracture have also been reported.